 | Up a level |
Niebuhr, A; Henry, T; Goldman, J; Baumgartner, I; van Belle, E; Gerss, J; Hirsch, A T; Nikol, S (2012). Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease. Gene therapy, 19(3), pp. 264-70. London: Nature Publishing Group 10.1038/gt.2011.85
Van Belle, E; Nikol, S; Norgren, L; Baumgartner, I; Driver, V; Hiatt, W R; Belch, J (2011). Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia. European journal of vascular and endovascular surgery EJVES, 42(3), pp. 365-73. London: Elsevier 10.1016/j.ejvs.2011.04.030
Keo, HH; Hirsch, AT; Baumgartner, I; Nikol, S; Henry, TD (2009). Gene Therapy in Critical Limb Ischemia. Vascular disease management, 2009(6), pp. 118-24. Malvern, Pa.: HMP Communications
Nikol, S; Baumgartner, I; Van Belle, E; Diehm, C; Visona, A; Capogrossi, M.C.; Ferreira-Maldent, N; Gallino, A; Wyatt, M.G.; Wijesinghe, L.D.; Fusari, M; Stephan, D; Emmerich, J; Pompilio, G; Vermassen, F; Pham, E; Grek, V; Coleman, M; Meyer, F (2008). Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Molecular therapy, 16(5), pp. 972-8. New York, N.Y.: Nature Publishing Group 10.1038/mt.2008.33
